Romosozumab
Treatment for Osteoporosis
Typical Dosage: 210 mg subcutaneous injection once monthly
Effectiveness
75%
Safety Score
55%
Clinical Trials
30
Participants
12K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
55
DangerousModerateSafe
Treatment Details
Dosage Range
210 mg subcutaneous injection once monthly
Time to Effect
3-6 months
Treatment Duration
12 months (followed by anti-resorptive)
Evidence Quality
HIGHNumber Needed to Treat (NNT)
10(Treat 10 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
200(Treat 200 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$27,000
Monitoring:$500
Side Effect Mgmt:$200
Total Annual:$27,700
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$250,000/QALY
QALYs Gained
0.3
Romosozumab Outcomes
for Osteoporosis
Efficacy Outcomes
Overall Effectiveness
+75%
Common Side Effects
Arthralgia
+14%
Headache
+10%
Injection site reactions
+7%
Myocardial infarction
+0.8%
Stroke
+0.8%
Osteonecrosis of the jaw (ONJ)
+0.05%
Atypical femoral fracture (AFF)
+0.01%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
10 active trials recruiting for Romosozumab in Osteoporosis
The Optimised Use of Romozosumab Study
NCT06059222RECRUITINGPHASE4
270 participants
INTERVENTIONAL
Aarhus, Denmark
Started: Oct 2, 2023
Romosozumab and Denosumab, Alone or Combined, in Postmenopausal Osteoporosis
NCT07283887RECRUITINGPHASE4
90 participants
INTERVENTIONAL
Douliu, Taiwan
Started: Dec 3, 2025
A Study of Romosozumab in Women With Multiple Myeloma and Osteoporosis
NCT05775094ACTIVE NOT RECRUITINGPHASE1
10 participants
INTERVENTIONAL
Basking Ridge, United States +6 more
Started: Mar 7, 2023
Combined Anabolic Therapy
NCT06558188RECRUITINGPHASE4
50 participants
INTERVENTIONAL
Boston, United States
Started: Feb 3, 2025
Compare the Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of SAL023 and Italy-Manufactured Evenity in Healthy Subjects
NCT07384104ENROLLING BY INVITATIONPHASE1
118 participants
INTERVENTIONAL
Hefei, China
Started: Oct 19, 2025
Effects of Cycle Therapy vs Sequential Therapy With Romosozumab and Denosumab in Postmenopausal Osteoporosis Patients
NCT06938152RECRUITINGPHASE4
70 participants
INTERVENTIONAL
Taipei, Taiwan
Started: Apr 8, 2025
Romosozumab Versus Denosumab in GIOP: a 2-year Extension Study
NCT06472050RECRUITINGPHASE4
63 participants
INTERVENTIONAL
Hong Kong, China
Started: Aug 20, 2024
Anabolic Therapy in Postmenopausal Osteoporosis
NCT05010590ACTIVE NOT RECRUITINGPHASE4
50 participants
INTERVENTIONAL
Boston, United States
Started: Mar 24, 2022
Romosozumab Effects on Bone Density, Muscle Mass, and Spine Surgery Outcomes
NCT06973109NOT YET RECRUITINGPHASE2
36 participants
INTERVENTIONAL
Pittsburgh, United States
Started: Mar 20, 2026
Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI
NCT05101018ACTIVE NOT RECRUITINGPHASE4
40 participants
INTERVENTIONAL
West Orange, United States +1 more
Started: Nov 1, 2021
Completed Clinical Trials
10 completed trials for Romosozumab in Osteoporosis
Transition From Alendronate to Romosozumab (AMG 785)
NCT01588509COMPLETEDPHASE1
60 participants
INTERVENTIONAL
Tucson, United States +8 more
Started: Mar 30, 2012
A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fracture.
NCT06079476COMPLETEDPHASE4
100 participants
INTERVENTIONAL
Ahmedabad, India +9 more
Started: Oct 30, 2023
Study of Romosozumab (AMG 785) Administered to Healthy Participants and Patients With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis
NCT01833754COMPLETEDPHASE1
24 participants
INTERVENTIONAL
Tempe, United States +4 more
Started: Apr 22, 2013
A Study to Test the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women With Osteoporosis
NCT05067335COMPLETEDPHASE3
327 participants
INTERVENTIONAL
Beijing, China +29 more
Started: Oct 21, 2021
Romosozumab Versus Denosumab for Osteoporosis in Long-term Glucocorticoid Users
NCT04091243COMPLETEDPHASE4
70 participants
INTERVENTIONAL
Hong Kong, China
Started: Jan 15, 2021
A Safety and Efficacy Study to Evaluate Romosozumab (AMG 785) in South Korean Women With Osteoporosis
NCT02791516COMPLETEDPHASE3
67 participants
INTERVENTIONAL
Busan, South Korea +9 more
Started: Jan 16, 2017
A Study to Compare the Safety and Efficacy of Romosozumab (AMG 785) Versus Placebo in Men With Osteoporosis
NCT02186171COMPLETEDPHASE3
245 participants
INTERVENTIONAL
Lakewood, United States +33 more
Started: Jun 16, 2014
Efficacy, Safety and Tolerability of Romosozumab in the Treatment of Japanese Women With Postmenopausal Osteoporosis
NCT01992159COMPLETEDPHASE2
252 participants
INTERVENTIONAL
Anjyo-shi, Japan +26 more
Started: Oct 12, 2012
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
NCT01575834COMPLETEDPHASE3
7.18K participants
INTERVENTIONAL
Tucson, United States +217 more
Started: Mar 15, 2012
A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis
NCT03432533COMPLETEDPHASE3
283 participants
INTERVENTIONAL
Birmingham, United States +45 more
Started: Feb 6, 2018
Showing 20 of 32 total trials